Metabolic Aging & Geroprotectors▲
Longevica Forms Scientific Advisory Board to Advance Longevity Pipeline
Longevica Therapeutics announced the formation of its Scientific Advisory Board, marking the preclinical biotech's pivot from foundational discovery to clinical execution and drug development. The company invested four years and $13 million in what it calls the world's largest in vivo mammalian screening program at The Jackson Laboratory, tracking 1,033 small-molecule compounds across more than 16,000 subjects over their natural lifespans. From that screen, 60-plus compounds extended mammalian lifespan by over 10% to 22%, and the company is now pursuing two novel classes of health-and-lifespan therapeutics alongside targeted drug repurposing for cardiovascular, metabolic, fibrotic, and systemic disease. The advisory board spans scientific, clinical, strategy, and business roles, including Dr. Steven Garan of UC Berkeley as Chief Scientific and Technology Advisor, Dr. Mike Zack as Chief Medical and Scientific Advisor, and Allan Gobbs of ATEM Capital as Corporate Strategy and Finance Advisor. The move follows the recent appointment of former Genentech, Roche, and NCI/NIH leader Dr. Prasun Mishra as Chief Executive Officer.
About megatrends
Longevity & Life Extension › Metabolic Aging & Geroprotectors ▲Technology
Longevica Therapeutics · Technology · Positive Longevica formed a Scientific Advisory Board to advance its longevity drug pipeline from preclinical discovery to clinical execution, with 60-plus compounds extending mammalian lifespan.